Translational research, laboratory development and clinical follow-up
EspañolCELLMEX conducts and supports laboratory, translational and clinically informed research involving cellular and cell-free regenerative technologies. Our work connects laboratory development, scientific review, physician collaboration, patient evaluation and structured follow-up.
CELLMEX approaches regenerative medicine as a translational process. A biological concept begins with scientific review, laboratory investigation and careful definition of the proposed mechanism, product or clinical objective.
Laboratory work may then examine cell behaviour, culture conditions, secreted factors, extracellular-vesicle fractions, formulation, storage, stability or tissue-specific biological responses.
Where a project advances toward clinical use, physicians review the proposed application, patient population, risks, alternatives, administration method, monitoring requirements and available evidence.
Patient follow-up then provides clinically relevant information concerning safety, tolerability, functional change, symptom evolution and the need for continuing medical care.
CELLMEX approaches regenerative-medicine research as a staged scientific process. Laboratory observations, biological characterization and clinical experience are evaluated within their appropriate context before conclusions are advanced toward broader clinical application.
A laboratory experiment is not evidence of clinical efficacy, an individual treatment programme is not automatically a clinical trial, and clinical observation does not replace controlled research. Our framework is intended to preserve these distinctions while allowing laboratory science, physician experience and structured clinical data to inform one another responsibly.
Research begins with a defined biological or clinical question rather than with a predetermined treatment claim.
Cellular and cell-free preparations are examined under defined laboratory conditions to understand identity, consistency and biological behaviour.
Where clinical investigation is appropriate, the scientific question is translated into a defined protocol with objectives, eligibility criteria and measurable outcomes.
Human research must proceed within the ethical, institutional and regulatory requirements applicable to the particular study, jurisdiction and product category.
Approved research activities require structured documentation of treatment exposure, safety observations, clinical outcomes and relevant follow-up.
Results are interpreted according to study design and evidentiary strength, including limitations, uncertainty and whether additional investigation is justified.
CELLMEX does not treat all scientific activity as equivalent. Mechanistic laboratory research, translational development, observational clinical follow-up and controlled clinical trials answer different questions and support different levels of conclusion. The strength of any statement should correspond to the strength of the evidence.
Claims and conclusions should remain proportional to the quality and maturity of the supporting evidence.
Human research requires attention to eligibility, informed consent, safety surveillance and appropriate medical oversight.
Biological source, processing, preparation, administration and resulting data should be documented in a traceable manner.
Promising laboratory findings should be translated progressively rather than represented prematurely as proven clinical benefit.
Each research area has distinct biological, analytical, manufacturing, clinical and regulatory requirements.
CELLMEX investigates and evaluates MSC-related processes relevant to research and potential clinical application.
Research focuses on the identity, separation, concentration and biological characteristics of extracellular-vesicle preparations.
CELLMEX evaluates the broader collection of soluble and vesicular components released by cultured cells.
Research may examine controlled culture conditions intended to influence lineage-associated characteristics or cellular phenotype.
Selected projects may involve the isolation, activation, expansion or functional evaluation of immune-cell populations.
A biologically active preparation must also be evaluated as a usable and reproducible final presentation.
Laboratory work may include cell culture, biological processing, microscopic observation, sample preparation, preservation research and development of cellular or cell-derived preparations.
Where specialised analytical capabilities are required, CELLMEX may collaborate with qualified external laboratories for testing, method development or independent assessment.
Physician-led patient evaluation, treatment, monitoring and follow-up occur in appropriate clinical settings rather than inside routine laboratory work areas.
Collaborating physicians and institutions may contribute diagnostic information, clinical evaluation, follow-up observations and indication-specific expertise.
Universities and research centres may participate in defined in-vitro, ex-vivo, analytical or translational projects.
Where appropriate, patient progress may be reviewed through structured remote consultations and communication with the patient's local physician.
The exact pathway depends on whether the project is a research preparation, clinical service, biological product, laboratory method or formal clinical study.
Development begins by identifying a biological question, clinical problem or technology gap.
Published evidence is reviewed to determine what is known, uncertain or unsupported.
The proposed preparation or process is defined before laboratory optimisation begins.
Source material affects the identity, consistency and safety of the resulting preparation.
Laboratory work establishes and refines the conditions used to produce or isolate the intended biological preparation.
The resulting material must be described using methods appropriate to the technology.
Where technically feasible, testing evaluates whether the preparation demonstrates the intended biological activity.
A final preparation must remain compatible with its intended storage, transport and use.
Before proposed clinical use, the available safety, quality and process information is reviewed.
Physicians and responsible reviewers evaluate whether a proposed clinical application is medically and ethically supportable.
Clinical use, where appropriate and authorised, should follow a defined patient-specific or protocol-based pathway.
Clinical and laboratory findings are reviewed to identify safety issues, inconsistencies, limitations and opportunities for process improvement.
Protocol content varies by technology, objective and jurisdiction. The framework below is general and does not constitute a treatment protocol.
Follow-up is necessary to evaluate safety, tolerability, clinical course and the continuing need for standard medical care.
Patients may be observed for acute reactions, procedural complications, vital-sign changes or other immediate concerns.
Early review may assess pain, swelling, fever, allergic symptoms, infection-related concerns and medication needs.
Depending on the condition, follow-up may include mobility, pain, symptom, quality-of-life, laboratory or imaging measures.
Longer follow-up may examine durability, progression of the underlying condition, delayed events and continuing treatment needs.
With appropriate patient authorisation, CELLMEX may communicate relevant treatment, monitoring and follow-up information to the patient's referring or local physician.
Regenerative medicine follow-up should not replace appropriate specialist care, standard treatment or emergency medical evaluation.
Physicians may provide diagnostic information, prior-treatment history, specialist assessment and continuing follow-up.
Disease-area specialists may contribute to patient selection, protocol design, safety review and clinical interpretation.
Institutions may support clinical evaluation, treatment delivery, monitoring, imaging, laboratory testing and emergency preparedness.
Academic partners may contribute methodology, specialist assays, study design, statistical review and publication expertise.
External laboratories may perform specialised characterisation, microbiological, molecular or functional testing.
Technology partners may contribute equipment, reagents, process knowledge, analytical methods or product-development experience.
Research and clinical records should permit reconstruction of what material was used, how it was processed and what occurred.
Research methods, qualified methods and formally validated methods must not be described as though they are equivalent.
Human research or investigational clinical activity may require formal ethical, institutional or regulatory review.
Findings should be interpreted in relation to study design, product identity, sample size, controls and known limitations.
| Research Level | Principal Question | Typical Output | Limitation |
|---|---|---|---|
| In-vitro Research | What occurs in cells or controlled laboratory systems? | Mechanistic, molecular or cellular findings | Does not prove clinical benefit |
| Ex-vivo Research | How does biological material behave outside the body under controlled conditions? | Tissue, blood, cell or sample-based results | May not reproduce whole-patient biology |
| Preclinical Research | Is there sufficient biological and safety rationale to consider clinical study? | Laboratory and model-based evidence | Translation to humans remains uncertain |
| Clinical Observation | What occurred in an individual or small group receiving care? | Safety, tolerability and outcome observations | Limited controls and generalisability |
| Prospective Clinical Study | What occurs under a predefined protocol? | Structured safety and outcome data | Strength depends on study design and size |
| Controlled Clinical Trial | How does the intervention compare with a control or alternative? | Comparative clinical evidence | Results apply to the studied product, population and protocol |
A laboratory project, patient treatment or clinical observation programme is not automatically a clinical trial.
A formal clinical trial requires a defined protocol, appropriate ethical and regulatory review, participant protection, documentation, monitoring and data analysis.
In-vitro research generally studies cells, molecules or biological systems under laboratory conditions.
Ex-vivo research studies tissues, cells or biological materials removed from the body while attempting to preserve relevant biological characteristics.
Projects are considered according to scientific rationale, feasibility, available expertise, laboratory capability, clinical relevance, ethical considerations and required resources.
No. The evidence level differs substantially between technologies, products and proposed applications.
Some areas may have meaningful clinical literature, while others remain primarily laboratory, preclinical or investigational.
Follow-up may include immediate observation, early safety review, symptom assessment, functional evaluation, laboratory studies, imaging and communication with the patient's regular physician.
Yes. Physicians may propose patient referrals, case review, protocol development, clinical observation, research collaboration or indication-specific consultation.
Yes. A proposal should define the research question, methods, biological materials, expected outputs, responsibilities, funding, intellectual-property considerations and required approvals.
No. Laboratory findings may support a mechanism or research hypothesis, but clinical safety and efficacy require appropriate human evidence.
Research and clinical information should be collected, accessed, transferred and stored under appropriate privacy, confidentiality and authorisation procedures.
Identifiable patient information should not be disclosed in publications or presentations without proper legal and ethical authority.
Ownership depends on the project, inventorship, employment terms, funding, source materials and collaboration agreement.
Intellectual-property and publication rights should be agreed in writing before substantive collaborative work begins.
This page describes the general CELLMEX research and development approach. It does not state that every method, assay, product, treatment or clinical application has been formally validated, approved or demonstrated to be effective. The status and reliability of our cellular, non-cell or genomic projects must be established through its protocol, laboratory records, quality documentation, clinical evidence and applicable regulatory requirements.
In a mature clinical programme, this work is typically performed by a multidisciplinary team, rather than a single scientist, comprising a Molecular Biologist/Molecular Genetics Scientist responsible for DNA extraction, PCR, library preparation and molecular QC; a Genomics/NGS Scientist responsible for sequencing workflows, assay performance and data quality; a Bioinformatician/Computational Biologist responsible for analysing sequencing data and identifying tumour-specific genomic variants; and a Molecular Pathologist/Clinical Molecular Geneticist responsible for clinical interpretation and oversight. Research programmes may use a more flexible team structure; however, when results are intended for clinical diagnosis or patient management, validated methods, formal quality systems, regulatory compliance and appropriately qualified clinical oversight are essential..
Scientific findings involving one product, donor, manufacturing process or formulation cannot automatically be attributed to another preparation.
Physicians, researchers, institutions and laboratories may submit an initial enquiry for CELLMEX review.
Ciudad de México
Zona La Reforma, CDMX
México
In-vitro Research · Ex-vivo Research · Clinical Collaboration · Laboratory Testing · Protocol Development